Novartis’ Cemiplimab Approved in China for Moderate-to-Severe Atopic Dermatitis
Novartis (SWX: NOVN, NYSE: NVS)’s Chinese arm has announced that it has received approval from...
September 2024
Innovent Biologics Launches Phase I Clinical Trial for IBR822 Cell Injection Solution in Solid Tumors
Innovent Biologics (Hangzhou) Co., Ltd (HKG: 1801, OTCMKTS: IVBXF), a biopharmaceutical company based in China,...
Johnson & Johnson’s Tremfya Gains FDA Approval for Ulcerative Colitis Treatment
Johnson & Johnson (NYSE: JNJ) announced today that the US Food and Drug Administration (FDA)...
Sanofi Secures Global Rights to Radioligand Therapy AlphaMexi in Deal with RadioMedix and Orano Med
Sanofi (EPA: SAN; NASDAQ: SNY), a leading French pharmaceutical company, has entered into a significant...
Roche’s Tecentriq Hybreza Becomes First Subcutaneous Anti-PD-(L)1 Immunotherapy in the US
Roche (SWX: ROG; OTCMKTS: RHHBY) , a leading Swiss pharmaceutical company, has secured US Food...
Lilly’s Once-Monthly Atopic Dermatitis Treatment Ebglyss Gets Green Light from FDA
Eli Lilly & Co. (NYSE: LLY) has announced that it has received market approval from...
Roche’s Ocrevus Zunovo Receives FDA Nod as First Twice-Yearly MS Treatment
Roche Group (SWX: ROG; OTCMKTS: RHHBY) , a Swiss pharmaceutical giant, has announced that the...
Ascentage Pharma’s Olverembatinib Shows Promise in SDH-Deficient GIST at ESMO Congress
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced the presentation of...
Fosun Pharma to Acquire Full Stake in Fosun Kite Biotechnology for USD 27 Million
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has disclosed plans to acquire...
Jiangsu Hengrui’s HER2-Targeted ADC SHR-A1811 Receives Priority Review from China’s NMPA
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
Hangzhou-Based Ophthalmic Device Maker MDCO Secures RMB 200 Million in Series B Funding
MDCO, an ophthalmic medical device company headquartered in Hangzhou, has reportedly secured nearly RMB 200...
Beijing Wantai Biological and Fujian Provincial CDC Collaborate on Vaccine Development and Public Health Initiatives
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a leading biopharmaceutical company based in...
MGI Tech and Haihe Laboratory Deepen Collaboration with Introduction of CycloneSEQ-WT02
MGI Tech Co., Ltd, a prominent gene sequencing company based in China, has disclosed a...
MGI Tech and Sequanta Technologies Launch Advanced DCS Lab to Accelerate Omics Research
MGI Tech Co., Ltd, a leading gene sequencing specialist based in China, has entered into...
China Boosts Public Health Subsidies and Targets Weight Management in 2024
The National Health Commission, Ministry of Finance, National Administration of Traditional Chinese Medicine, and National...
China’s NHSA and MOF Issue Notices to Enhance Cross-Regional Medical Treatment Direct Settlement
The National Healthcare Security Administration (NHSA) and the Ministry of Finance (MOF) have issued two...
CDE Launches CARE Plan to Streamline Rare Disease Drug Development
The Center for Drug Evaluation has unveiled the ‘Pilot Work Plan for Patient-Centered Action for...
Moderna Inc. Announces Cost-Cutting Measures and Pipeline Realignment
Moderna Inc. (NASDAQ: MRNA), a leading mRNA technology company based in the U.S., has announced...
Sino Biological and BioGeometry Broaden Partnership to Advance AI-Driven Drug Discovery
Sino Biological (SHE: 301047), a leading biotech company in China, and BioGeometry have announced an...
Johnson & Johnson Submits Second NDA for Nipocalimab to Treat Generalized Myasthenia Gravis
Johnson & Johnson (NYSE: JNJ), a leading healthcare company based in the U.S., has reported...